DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-634/S-028
NDA 20-635/S-027

Johnson & Johnson Pharmaceutical Research and Development
Attention: Robyn S. Keown, Sr. Regulatory Associate, Regulatory Affairs
920 Rte. 202 South, PO Box 300
Raritan, N J 08869-0602

Dear Ms. Keown:

Please refer to your supplemental new drug applications, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

NDA Number	Supplement Number	Date of Supplement	Date of Receipt	Name of Drug Product
20-634	S-028	December 20, 2002	December 23, 2002	Levaquin (levofloxacin) Tablets
20-635	S-027	December 23, 2002	December 23, 2002	Levaquin (levofloxacin) Injection and Levaquin (levofloxacin in 5% dextrose injection) Injection

We acknowledge receipt of your submissions dated:

April 4, 2003
April 24, 2003
June 6, 2003
August 19, 2003
October 16, 2003
October 21, 2003 (2)

These supplemental new drug applications provide for the use of Levaquin Tablets and Injection for Community Acquired Pneumonia (CAP) with a new dosing regimen of 750 mg, once daily for 5 days.

We have completed the review of these applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the agreed upon labeling text (enclosed). Accordingly, these applications are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, submitted on October 21, 2003).

Please submit the FPL electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – NDA.* Alternatively, you may submit 20 paper copies

of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplement NDA 20-634/S-028, NDA 20-635/S-027." Approval of these submissions by the FDA is not required before the labeling is used.

We remind you of your postmarketing study commitment dated October 21, 2003, submitted in follow-up to our teleconference of October 21, 2003. During that teleconference, we discussed the need to investigate the efficacy observed in patients with renal impairment who received 750 mg every 48 hours. This commitment is listed below:

1. Conduct a pharmacokinetic study utilizing the LEVAQUIN 750 mg dose in otherwise healthy, renally-impaired patients to characterize drug exposure following the dosage adjustments recommended in the product label.

Protocol Submission:	Within 6-9 months of the date of this letter
Study Start:	Within 10-12 months of the date of this letter
Final Report Submission:	Within 24-26 months of the date of this letter

Submit clinical protocols to your INDs for these products. Submit nonclinical and chemistry, manufacturing, and controls protocols and all study final reports to these NDAs. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual reports to these NDAs. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to these postmarketing study commitments must be prominently labeled "**Postmarketing Study Protocol**", "**Postmarketing Study Final Report**", or "**Postmarketing Study Correspondence**."

FDA's Pediatric Rule at 21 CFR 314.55 was challenged in court. On October 17, 2002, the court ruled that FDA did not have the authority to issue the Pediatric Rule and has barred FDA from enforcing it. Although the government decided not to pursue an appeal in the courts, it will work with Congress in an effort to enact legislation requiring pharmaceutical manufacturers to conduct appropriate pediatric clinical trials. In addition, third party interveners have decided to appeal the court's decision striking down the rule. Therefore, if you do not conduct pediatric clinical trials as outlined in your Written Request, we encourage you to submit a pediatric plan that describes development of your product in the pediatric population where it may be used. Please be aware that whether or not this pediatric plan and subsequent submission of pediatric data will be required depends upon passage of legislation or the success of the third party appeal. In any event, we hope you will conduct the appropriate pediatric studies to provide important information on the safe and effective use of this drug in the relevant pediatric populations.

The pediatric exclusivity provisions of FDAMA as reauthorized by the Best Pharmaceuticals for Children Act are not affected by the court's ruling. We acknowledge your Written Request, dated December 20, 2001, as part of which you will conduct a clinical trial in pediatric patients with community acquired pneumonia.

Please submit three copies of the introductory promotional materials that you propose to use for this new dosing regimen for these products. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

If you issue a letter communicating important information about these drug products (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to these NDAs and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Susan Peacock, Regulatory Project Manager, at (301) 827-2127.

Sincerely,

{See appended electronic signature page}

Renata Albrecht, M.D.
Director
Division of Special Pathogen and Immunologic Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

Enclosure (labeling)